Clinical Trials Browser

avelumab × Dermatologic × 90 days × Clear all

NCT05267626 2026-05-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Diabetes Mellitus, Insulin-Dependent, 10, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Carcinoma, Merkel Cell

NCT05947500 2026-05-13

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Phase 2 Active not recruiting

50 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT03271372 2026-05-12

ADAM

Phase 3 Active not recruiting

101 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT04291885 2026-04-09

I-MAT

Phase 2 Active not recruiting

122 enrolled

DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04792073 2026-04-07

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Phase 2 Active not recruiting

18 enrolled

Dermatologic

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Phase 1 Active not recruiting

210 enrolled

DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT04261855 2026-03-27

GoTHAM

Phase 1/2 Active not recruiting

19 enrolled

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Skin Neoplasms